Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

When the National Agency for Food and Drugs Administration and Control (NAFDAC) made a burnfire at the Aluu dumpsite near Port ...

The Trump Administration has implemented or proposed a broad range of tariffs, including on pharmaceuticals. Careful ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Some U.S. health regulators who review medical devices and tobacco products for safety and efficacy are struggling to meet ...

The maker of a new prescription drug product for people with life-threatening allergies is using copayment coupons to build ...

With over 15 years of expertise in developing injectable and liquid pharmaceutical forms, CARBOGEN AMCIS' Saint-Beauzire site ...

Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS ...

The U.S. Food and Drug Administration has granted approval to a new antibiotic to treat urinary tract infections in women and ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...